19 Oct 2021
Faster-than-anticipated recovery
Tissue Regenix (TRX) is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL) and bone (BioRinse). It has a broad portfolio of marketed regenerative medicine products for the biosurgery, orthopaedics and dental markets. Interim results showed early signs of the benefits of its strategic activities over the past two years – the focus on commercial relationships, capacity expansion, restructuring to service demand, and recovery in elective surgeries after the pandemic. If the demand and sales progress continues, TRX will become EBITDA- and EBIT-positive in fiscal 2022
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Faster-than-anticipated recovery
Tissue Regenix Group plc (TRX:LON) | 61.5 0 0.0% | Mkt Cap: 43.4m
- Published:
19 Oct 2021 -
Author:
Martin Hall -
Pages:
10
Tissue Regenix (TRX) is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL) and bone (BioRinse). It has a broad portfolio of marketed regenerative medicine products for the biosurgery, orthopaedics and dental markets. Interim results showed early signs of the benefits of its strategic activities over the past two years – the focus on commercial relationships, capacity expansion, restructuring to service demand, and recovery in elective surgeries after the pandemic. If the demand and sales progress continues, TRX will become EBITDA- and EBIT-positive in fiscal 2022